Guselkumab
Treatment for Psoriasis
Typical Dosage: 100mg SC at weeks 0, 4, then every 8 weeks
Effectiveness
88%
Safety Score
60%
Clinical Trials
61
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
100mg SC at weeks 0, 4, then every 8 weeks
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
80(Treat 80 patients to see 1 additional serious adverse event)
Confidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$97,000
Monitoring:$600
Side Effect Mgmt:$500
Total Annual:$98,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$155,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$116,786
Cost per Remission
$245,250
Guselkumab Outcomes
for Psoriasis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+84%
Remission Rate
+40%
Common Side Effects
Upper respiratory tract infection
+12.6%
Headache
+10.4%
Injection site reactions
+7.5%
Gastroenteritis
+3.4%
Active Clinical Trials
6 active trials recruiting for Guselkumab in Psoriasis
Guselkumab Immunogenetics
NCT04645355RECRUITINGPHASE4
25 participants
INTERVENTIONAL
San Francisco, United States
Started: Mar 1, 2021
Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
NCT06974474RECRUITINGPHASE4
26 participants
INTERVENTIONAL
Rome, Italy
Started: Jun 18, 2024
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
NCT03451851ACTIVE NOT RECRUITINGPHASE3
120 participants
INTERVENTIONAL
Palo Alto, United States +38 more
Started: Jul 11, 2018
Immune Spatial Features of Guselkumab Cutaneous Response
NCT05858632RECRUITINGPHASE4
10 participants
INTERVENTIONAL
San Francisco, United States
Started: Jul 1, 2023
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
NCT05270733RECRUITINGPHASE4
56 participants
INTERVENTIONAL
Cleveland, United States
Started: Nov 10, 2022
Multi-Center PAMPA Study
NCT05004727RECRUITINGPHASE4
176 participants
INTERVENTIONAL
Boston, United States +4 more
Started: Feb 16, 2022
Completed Clinical Trials
11 completed trials for Guselkumab in Psoriasis
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
NCT02325219COMPLETEDPHASE3
192 participants
INTERVENTIONAL
Asahikawa, Japan +26 more
Started: Dec 19, 2014
A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
NCT04439526COMPLETED
356 participants
OBSERVATIONAL
Bari, Italy +37 more
Started: Jun 10, 2020
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
NCT04914429COMPLETEDPHASE4
327 participants
INTERVENTIONAL
Beijing, China +25 more
Started: Aug 25, 2021
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT02343744COMPLETEDPHASE3
21 participants
INTERVENTIONAL
Asahikawa, Japan +19 more
Started: Jan 19, 2015
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
NCT05272150COMPLETEDPHASE3
213 participants
INTERVENTIONAL
Birmingham, United States +93 more
Started: Jul 13, 2022
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
NCT02905331COMPLETEDPHASE3
78 participants
INTERVENTIONAL
Ocala, United States +13 more
Started: Feb 28, 2017
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
NCT03818035COMPLETEDPHASE3
880 participants
INTERVENTIONAL
Antony, France +89 more
Started: Feb 8, 2019
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189COMPLETEDPHASE3
338 participants
INTERVENTIONAL
Birmingham, United States +63 more
Started: Aug 24, 2023
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
NCT03090100COMPLETEDPHASE3
1.05K participants
INTERVENTIONAL
Birmingham, United States +141 more
Started: Apr 27, 2017
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
NCT02203032COMPLETEDPHASE3
872 participants
INTERVENTIONAL
Birmingham, United States +84 more
Started: Oct 7, 2014
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
NCT03998683COMPLETEDPHASE3
117 participants
INTERVENTIONAL
Bordeaux, France +25 more
Started: Sep 3, 2019
Showing 20 of 62 total trials